Medical Oncologist
Your report explained
Rare breast cancer subtypes: mucinous, tubular, papillary and metaplastic
Most breast cancers are invasive ductal or lobular. A small share look different enough under the microscope to be named separately. Several of these behave more gently than the common types. One, metaplastic, is less predictable. This page explains what each name means and what the subtype genuinely changes in your treatment.
MM
Medically reviewed by Dr. Muralidhar MuddusettyConsultant Surgical Oncologist · MBBS (AIIMS), MS (Surgery, AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does a rare subtype on my report mean?
- The words around the diagnosis, in plain language
- The subtypes you are most likely to see named
- What stays the same and what changes
- What a rare diagnosis genuinely changes
- What people assume about a rare subtype
- Common questions about rare breast cancer subtypes
The short answer
What does a rare subtype on my report mean?
Most breast cancers are described as invasive ductal or invasive lobular. A small share look different enough under the microscope to be given their own name. Some of these behave more gently than the common types. One of them behaves less predictably.
Why the name matters less than you think
Your treatment is still built mainly from the same things: the size, the grade, whether nodes are involved and the receptor and HER2 results. The subtype name adjusts that picture rather than replacing it.
Why the name matters more than you think
For a few of these subtypes it genuinely changes the expected behaviour, and in one case it changes which treatments are likely to work. It is worth knowing which group you are in, and worth asking whether your centre has treated it before.
Rare here means uncommon, not untreatable. Most of these subtypes are treated in the same units by the same teams.On your report
The words around the diagnosis, in plain language
- Invasive ductal carcinoma, or IDC
- The most common breast cancer, beginning in a milk duct and breaking out into the surrounding tissue. This is the type all the others are described against.
- Invasive lobular carcinoma
- The second most common. It grows in strands rather than a firm lump, which is why it can be harder to see on a mammogram.
- Special type
- The phrase pathologists use for a cancer with a distinctive appearance of its own. Mucinous, tubular and papillary are all special types.
- Mixed type
- Part of the cancer looks like one type and part like another. Your treatment is usually planned around the component with the features needing the most treatment.
- Grade
- How abnormal the cells look under the microscope. It is reported separately from the subtype and often matters more.
- Triple negative
- No oestrogen receptor, no progesterone receptor and no HER2. Most metaplastic cancers fall into this group and are treated accordingly.
Not sure whether this applies to you?
Ask an oncologistThe main ones
The subtypes you are most likely to see named
These are descriptions of how the cancer looks and behaves, not separate diseases requiring separate hospitals.
Mucinous
The cancer cells sit in pools of mucus. It is usually hormone receptor positive, HER2 negative and low grade, and it tends to behave gently and reach the lymph nodes less often.
Usually means
- Hormone tablets are the mainstay
- Chemotherapy is less often needed
Tubular
The cells form small tube shapes. It is typically small, low grade and strongly hormone sensitive, and it is one of the most favourable breast cancers to be diagnosed with.
Often found through screening rather than as a lump.Papillary
The cells grow in finger-like fronds. Most are hormone sensitive and behave gently. It is seen more often in older women, and some forms sit on the boundary between in situ and invasive disease.
Metaplastic
The odd one out. These cancers often have no hormone receptors and no HER2, grow faster and respond less reliably to standard chemotherapy. They need a considered plan and are worth a second opinion.
Usually means
- Treated as triple negative disease
- Trials are worth asking about
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Side by side
What stays the same and what changes
Decided the same way as any breast cancer
Where the subtype can change things
Whether the breast can be kept
How likely chemotherapy is to be recommended
Whether the lymph nodes are examined
How useful a gene test is likely to be
Whether radiotherapy follows conservation
Whether a clinical trial is worth asking about
Whether hormone tablets are offered if receptors are present
How closely you are followed up afterwards
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being straight with you
What a rare diagnosis genuinely changes
The hardest part of an uncommon diagnosis is not the treatment. It is that there is less evidence behind every decision, and honest doctors will say so rather than projecting more certainty than exists.
Smaller studies, wider uncertainty
Trials in breast cancer recruit thousands of people with the common types. A subtype making up a small share of diagnoses is represented by far fewer, so recommendations lean more on experience and on how the cancer looks than on large trials. That is a real limitation.
Where a second opinion earns its place
For metaplastic cancer, and for any diagnosis your team says they see rarely, a second opinion at a centre that sees more of it is reasonable and will not offend anyone competent. Take the blocks and slides, not just the typed report.
What to be careful of online
Outcome figures for rare subtypes come from small groups, often collected over many years and across different standards of treatment. They swing widely and they are easy to misread. Ask your own oncologist what your report means for you rather than assembling a picture from studies you cannot weigh.
Commonly believed
What people assume about a rare subtype
Rare means dangerous.
Several of the uncommon subtypes are among the most favourable breast cancers there are. Mucinous and tubular cancers in particular tend to behave gently. Rare describes how often it is diagnosed, not how it behaves.
I need to go abroad for treatment.
These subtypes are treated with the same surgery, radiotherapy and drugs available here. What is worth seeking out is a team that has seen the subtype before and a tumour board that discusses it, not a different country.
A rare subtype means no standard treatment exists.
Guidelines cover them, usually by treating them according to their receptor results while adjusting for known behaviour. Your oncologist is not improvising. They are applying the same framework with fewer trials behind one part of it.
The figures I found online apply to me.
Numbers for rare subtypes come from small groups treated over long periods, and they vary enormously between studies. They are among the least reliable figures in cancer medicine to apply to one person.
Questions we are asked
Common questions about rare breast cancer subtypes
Is a rare subtype worse than ordinary breast cancer?
Usually not, and several are better. Mucinous, tubular and papillary cancers generally behave more gently than the common types. Metaplastic cancer is the one that needs a more careful plan. Ask which group yours falls into before assuming anything.
Will I need chemotherapy?
For the gentler subtypes it is often not needed, particularly where the cancer is small, low grade, hormone sensitive and the nodes are clear. For metaplastic cancer it is usually part of the plan. The receptor results matter more than the subtype name.
Should I get a second opinion?
It is worth it for metaplastic cancer, for any diagnosis that surprised your own team, or where the appearance and the receptor results seem inconsistent. Ask for the blocks and slides in writing so the tissue itself can be reviewed.
Is a gene test useful for my subtype?
These tests were developed mainly in the common hormone sensitive types, so they are less well validated in rare subtypes. Your oncologist may still use one where the decision is genuinely borderline. Ask what it would change before paying for it.
Does a rare subtype run in families?
Most do not. Genetic testing is offered on the basis of your age, family history and receptor results rather than the subtype name, with a few exceptions your oncologist will know. Ask for genetic counselling if any of those apply.
Can my subtype be confirmed?
Yes, and it is a fair request. These diagnoses are made by eye with the help of special stains, and uncommon ones are the most likely to be revised on review. A second pathologist looking at the same slides is a reasonable step.
Are clinical trials open to rare subtypes?
Some are, particularly for metaplastic and other triple negative cancers. Ask your oncologist whether anything is recruiting that you would qualify for, and ask early, because eligibility often depends on not having started certain treatments yet.
Will my follow-up be different?
The schedule is broadly the same, though a team may see you more often where the subtype is less predictable. What matters more is that you know which symptoms to report between visits rather than waiting for the next appointment.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Types of breast cancer
- National Cancer Institute — Breast cancer treatment (PDQ) - health professional version
- Breast Cancer Now — Rarer types of breast cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.